Supplementary Materials

The PDF file includes:

  • Fig. S1. Molecular weights are increased by CBD conjugation to αPD-L1 or fusion to IL-2.
  • Fig. S2. Affinities of CBD-αCTLA4, CBD–αPD-L1, and CBD–IL-2 for collagen I and III and their target proteins were determined.
  • Fig. S3. Both CBD–IL-2 and IL-2 proliferate and bind target cells.
  • Fig. S4. Distribution of CBD–αPD-L1 and αPD-L1 within the tumor was analyzed.
  • Fig. S5. Blood concentrations of injected CBD-CPI, CBD–IL-2, and their unmodified forms were analyzed.
  • Fig. S6. Leukocyte infiltration in the liver, lung, and kidney after unmodified CPI and CBD-CPI treatment was analyzed.
  • Fig. S7. Populations of leukocytes infiltrated into the liver after unmodified CPI or CBD-CPI treatment were analyzed.
  • Fig. S8. Conjugation of CBD to CPI is indispensable for B16F10 tumor growth suppression.
  • Fig. S9. EMT6 immune-excluded tumor is not very responsive to CBD-CPI and CBD–IL-2.
  • Fig. S10. CBD-CPI treatment decreases immunosuppressive MDSCs within B16F10 tumor.
  • Fig. S11. Immune cells within B16F10 tumor and spleen were analyzed after CBD–IL-2 treatment.
  • Fig. S12. CBD–IL-2 treatment increases the number of CD8+ T cells and NK cells within MMTV-PyMT tumor but not within EMT6 tumor.
  • Table S1. Protein sequences.

[Download PDF]

Other Supplementary Material for this manuscript includes the following: